Detalhe da pesquisa
1.
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
Br J Cancer
; 118(6): 770-776, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438361
2.
Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.
Nat Commun
; 15(1): 3173, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609390
3.
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.
BJUI Compass
; 4(3): 322-330, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025470
4.
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Nat Med
; 28(12): 2592-2600, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36526722
5.
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
Nat Med
; 26(2): 193-199, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32042196
6.
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Clin Cancer Res
; 26(22): 5869-5878, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816891
7.
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Eur J Cancer
; 109: 103-110, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30711772
8.
Publisher Correction: Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.
Nat Commun
; 15(1): 3448, 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658563
9.
Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma.
BMJ Case Rep
; 20132013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23682089